With the tremendous progress in anticancer treatment and the subsequent growing population of cancer survivors, the discipline of cardio-oncology in providing care to cancer patients with cardiovascular complications has developed at a remarkable pace. Cardiotoxicity related to traditional chemotherapy agents and shared risk factors for cancer and cardiovascular disease, such as eating processed meats, smoking, obesity, and pollution have been well described. However, great gaps remain in not only basic studies about the cardiovascular effects of various cancer treatments, but also clinical research involving the prevention and treatment of cardiovascular complications of cancers and associated new therapies.

In this Special Issue, we aim to provide a platform for researchers to present their results focused on basic, translational and clinical investigations associated with cancer treatment-related cardiotoxicity. We welcome the submission of original research and review articles from cardiologists, oncologists, pharmacists, and researchers.

Potential topics include but are not limited to the following:

• Describing clinical characteristics of cardiotoxicity related elementary and advanced cancer treatments
• Refining the predisposing factors for the development of cardiac conditions related to cancer treatments, such as prior myocardial infarction, electrolyte disturbance, etc.
• Evaluating robust predictors for cancer treatment-related cardiovascular complications
• Defining the most reliable cardiac monitoring approach (e.g., electrocardiogram, echocardiogram, and cardiac biomarkers)
• Describing cardiovascular therapies in patients with malignancy (e.g., statins, oral anticoagulation)
• Understanding the potential mechanisms and pathophysiology between cancer treatments and cardiotoxicity
• Discussing appropriate methods and timing for prevention and intervention of cancer-related cardiac conditions